{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q3-2021"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q3-2021","index":0,"n_rows":141,"n_cols":9,"rows_kept":141,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title","Conditions ","Enrollment ","Dates","Study Design"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","Recruiting",98,"Primary Completion: February 27, 2023\nStudy Completion: September 15, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04202679","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","Active, not recruiting",160,"Primary Completion: August 2021\nStudy Completion: November 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04183335","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable","Active, not recruiting",151,"Primary Completion: October 2021\nStudy Completion: July 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab","Recruiting",234,"Primary Completion: April 2022\nStudy Completion: July 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","Recruiting",924,"Primary Completion: October 2022\nStudy Completion: January 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 2\n","NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)","Active, not recruiting",149,"Primary Completion: October 16, 2020\nStudy Completion: October 6, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03633617","Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","Active, not recruiting",321,"Primary Completion: September 16, 2021\nStudy Completion: July 12, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","Active, not recruiting",381,"Primary Completion: October 2023\nStudy Completion: October 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)","Enrolling by invitation",800,"Primary Completion: November 3, 2026\nStudy Completion: November 3, 2026","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04442269","A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)","Recruiting",170,"Primary Completion: September 7, 2023\nStudy Completion: October 23, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","Recruiting",930,"Primary Completion: December 2023\nStudy Completion: May 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)","Recruiting",120,"Primary Completion: December 2022\nStudy Completion: May 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)","Recruiting",78,"Primary Completion: July 2022\nStudy Completion: October 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04678856","Dupilumab in CRSsNP (Liberty CRSsNP ORION)","Recruiting",240,"Primary Completion: July 31, 2023\nStudy Completion: September 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","SAR441344 (anti-CD40L mAb)","\nPhase 2\n","NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","Recruiting",88,"Primary Completion: August 2022\nStudy Completion: October 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients","Recruiting",25,"Primary Completion: February 1, 2023\nStudy Completion: December 5, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["I&I","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","Recruiting",72,"Primary Completion: January 2023\nStudy Completion: April 2027","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["I&I","Kevzara (anti-IL6 mAb) ","\nPhase 2\n","NCT02776735","An Open-label, Ascending, Repeated Dose- finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","Recruiting",100,"Primary Completion: March 31, 2022\nStudy Completion: February 6, 2024","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["I&I","SAR444727 (BTK inhibitor - topical)","\nPhase 2\n","NCT04992546","Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis","Recruiting",40,"Primary Completion: August 2022\nStudy Completion: August 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","SAR443122 (RIPK1 inhibitor)","\nPhase 2\n","NCT04781816","Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus","Recruiting",88,"Primary Completion: April 11, 2022\nStudy Completion: May 12, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","SAR444656 (IRAK4 degrader)","\nPhase 1\n","NCT04772885","A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","Recruiting",124,"Primary Completion: February 1, 2022\nStudy Completion: February 1, 2022","• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)","Recruiting",1170,"Primary Completion: February 2024\nStudy Completion: July 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","SAR445229 (anti-OX40L mAb)","\nPhase 2\n","NCT03754309","A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis","Completed",89,"Primary Completion: May 12, 2020\nStudy Completion: October 8, 2020","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["I&I","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","Recruiting",924,"Primary Completion: February 2023\nStudy Completion: May 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","Recruiting",46,"Primary Completion: January 2023\nStudy Completion: November 2023","• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","Active, not recruiting",25,"Primary Completion: September 6, 2020\nStudy Completion: May 2, 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","Active, not recruiting",662,"Primary Completion: May 2025\nStudy Completion: December 2025","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","Active, not recruiting",475,"Primary Completion: December 2022\nStudy Completion: January 2025","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","Active, not recruiting",307,"Primary Completion: November 22, 2018\nStudy Completion: March 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT02812706","Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","Active, not recruiting",32,"Primary Completion: July 31, 2018\nStudy Completion: October 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02514668","A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","Active, not recruiting",55,"Primary Completion: December 30, 2021\nStudy Completion: December 30, 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","Active, not recruiting",76,"Primary Completion: January 2023\nStudy Completion: January 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT01749969","SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","Active, not recruiting",60,"Primary Completion: June 30, 2022\nStudy Completion: June 30, 2022","• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","Active, not recruiting",351,"Primary Completion: December 21, 2018\nStudy Completion: December 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04294459","Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","Recruiting",42,"Primary Completion: July 22, 2022\nStudy Completion: July 22, 2022","• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04270409","Isatuximab in Combination With Lenalidomide and Dexamethasone in High- risk Smoldering Multiple Myeloma","Recruiting",323,"Primary Completion: June 2028\nStudy Completion: October 2033","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT04154943","Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma","Active, not recruiting",80,"Primary Completion: December 2, 2021\nStudy Completion: September 4, 2025","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03969004","Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma","Recruiting",412,"Primary Completion: December 19, 2025\nStudy Completion: February 28, 2027","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 2\n","NCT03860844","Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","Recruiting",96,"Primary Completion: August 31, 2023\nStudy Completion: August 31, 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03769181","A Study of Isatuximab-based Therapy in Participants With Lymphoma","Active, not recruiting",130,"Primary Completion: February 15, 2021\nStudy Completion: October 24, 2022","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT03637764","Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","Active, not recruiting",350,"Primary Completion: May 2022\nStudy Completion: May 2022","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","Active, not recruiting",302,"Primary Completion: March 1, 2022\nStudy Completion: February 7, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 1\n","NCT03233139","Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies","Recruiting",81,"Primary Completion: August 1, 2023\nStudy Completion: August 1, 2023","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT02760498","Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma","Recruiting",433,"Primary Completion: October 20, 2025\nStudy Completion: December 1, 2025","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04524689","Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and\nPlatinum-based Chemotherapy in Patients With NSQ NSCLC (CARMEN-LC05)","Recruiting",78,"Primary Completion: April 2022\nStudy Completion: March 2024","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04394624","SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","Recruiting",36,"Primary Completion: April 21, 2022\nStudy Completion: October 21, 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 3\n","NCT04154956","SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non- small Cell Lung Cancer Patients","Recruiting",554,"Primary Completion: April 2022\nStudy Completion: March 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 2\n","NCT03430063","A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer","Active, not recruiting",28,"Primary Completion: November 1, 2021\nStudy Completion: November 1, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","Active, not recruiting",790,"Primary Completion: May 1, 2023\nStudy Completion: May 1, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 1\n","NCT03324113","Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","Active, not recruiting",63,"Primary Completion: August 2022\nStudy Completion: October 2022","• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer","Active, not recruiting",590,"Primary Completion: May 31, 2021\nStudy Completion: July 7, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR439459 (anti-TGFb mAb)","\nPhase 1\n","NCT03192345","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors","Recruiting",350,"Primary Completion: April 2023\nStudy Completion: May 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Libtayo (anti-PD-1 mAb)","\nPhase 3\n","NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting",712,"Primary Completion: November 1, 2022\nStudy Completion: November 1, 2022","• Allocation: Randomized\n• Intervention Model: Crossover Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\n• Phase 1\n• Phase 2\n","NCT02187848","Evaluation of SAR408701 in Patients With Advanced Solid Tumors","Active, not recruiting",263,"Primary Completion: March 31, 2022\nStudy Completion: March 31, 2022","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","amcenestrant (SERD)","\nPhase 3\n","NCT04478266","Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer","Recruiting",1066,"Primary Completion: January 2024\nStudy Completion: May 2027","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT04418661","Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies","Recruiting",88,"Primary Completion: July 15, 2025\nStudy Completion: July 15, 2025","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","amcenestrant (SERD)","\nPhase 2\n","NCT04059484","Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","Recruiting",372,"Primary Completion: November 2021\nStudy Completion: July 2025","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Oncology","SAR444245 (Non-alpha IL-2)","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors","Recruiting",200,"Primary Completion: June 2022\nStudy Completion: June 2022","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR442085 (anti-CD38 mAb Fc engineered)","\nPhase 1\n","NCT04000282","First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma","Recruiting",78,"Primary Completion: January 26, 2023\nStudy Completion: May 16, 2023","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR442720 (SHP2 inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03989115","Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC","Active, not recruiting",168,"Primary Completion: March 31, 2022\nStudy Completion: April 30, 2022","• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR441000 (Cytokine mRNA)","\nPhase 1\n","NCT03871348","A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","Recruiting",231,"Primary Completion: June 2022\nStudy Completion: January 2024","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","amcenestrant (SERD)","\nPhase 1\n","NCT03816839","Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer","Active, not recruiting",12,"Primary Completion: October 27, 2020\nStudy Completion: December 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR442720 (SHP2 inhibitor)","\nPhase 1\n","NCT03634982","Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","Recruiting",175,"Primary Completion: October 1, 2021\nStudy Completion: October 1, 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","amcenestrant (SERD)","\n• Phase 1\n• Phase 2\n","NCT03284957","Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","Recruiting",251,"Primary Completion: January 2024\nStudy Completion: January 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR443216 (anti-CD3xCD28xHer2 trispecific mAb)","\nPhase 1\n","NCT05013554","Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/ Refractory HER2 Expressing Solid Tumors","Recruiting",184,"Primary Completion: June 16, 2025\nStudy Completion: June 16, 2025","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR444245 (Non-alpha IL-2)","\n• Phase 1\n• Phase 2\n","NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of\nParticipants With Various Advanced Skin Cancers","Recruiting",80,"Primary Completion: June 23, 2023\nStudy Completion: July 9, 2024","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04751877","Study of Isatuximab+Lenalidomide\n+Dexamethasone With/Without Bortezomib in de Novo Non Frail NTE Multiple Myeloma Elderly Patients","Recruiting",270,"Primary Completion: April 2, 2024\nStudy Completion: July 16, 2026","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR444881 (anti-ILT2 mAb)","\n• Phase 1\n• Phase 2\n","NCT04717375","Study of BND-22 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors","Recruiting",130,"Primary Completion: September 2023\nStudy Completion: January 2024","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","tusamitamab ravtansine (anti-CEACAM5 ADC)","\nPhase 2\n","NCT04659603","SAR408701 in Patients With CEACAM5- positive Advanced Solid Tumors","Recruiting",64,"Primary Completion: January 2025\nStudy Completion: January 2025","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","Recruiting",117,"Primary Completion: January 2026\nStudy Completion: January 2026","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR442257 (anti CD38xCD28xCD3 trispecific mAb)","\nPhase 1\n","NCT04401020","First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","Recruiting",57,"Primary Completion: January 2024\nStudy Completion: April 2024","• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","SAR445419 (NK-cell-based immunotherapy)","\nPhase 1\n","NCT04220684","Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","Recruiting",44,"Primary Completion: December 31, 2021\nStudy Completion: December 31, 2021","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Oncology","Alomfilimab (SAR445256/Anti-ICOS mAb)","\n• Phase 1\n• Phase 2\n","NCT03829501","Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer","Recruiting",412,"Primary Completion: May 2023\nStudy Completion: May 2023","• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["MS & Neuro","SAR441344 (anti-CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis","Recruiting",120,"Primary Completion: May 2022\nStudy Completion: December 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["MS & Neuro","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Recruiting",90,"Primary Completion: May 2024\nStudy Completion: May 2024","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["MS & Neuro","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","Recruiting",990,"Primary Completion: August 2024\nStudy Completion: August 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["MS & Neuro","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","Recruiting",1290,"Primary Completion: August 2024\nStudy Completion: August 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["MS & Neuro","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","Recruiting",900,"Primary Completion: August 2023\nStudy Completion: August 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["MS & Neuro","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","Recruiting",900,"Primary Completion: August 2023\nStudy Completion: August 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["MS & Neuro","tolebrutinub (BTK inhibitor)","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis","Active, not recruiting",125,"Primary Completion: April 2025\nStudy Completion: April 2025","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare disease","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT04221451","A Multinational, Randomized, Double- blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics,\nPharmacokinetics, and Safety of Venglustat in Late-onset GM2","Recruiting",77,"Primary Completion: January 2024\nStudy Completion: January 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Rare disease","Nexviazyme (Enzyme Replacement Therapy) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","Active, not recruiting",22,"Primary Completion: September 30, 2019\nStudy Completion: December 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare disease","SAR339375 (miR21 RNA) ","\nPhase 2\n","NCT02855268","Study of Lademirsen (SAR339375) in Patients With Alport Syndrome","Recruiting",45,"Primary Completion: December 4, 2023\nStudy Completion: December 4, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment"]
["Rare disease","venglustat (oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3","Active, not recruiting",13,"Primary Completion: January 11, 2024\nStudy Completion: January 11, 2024","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare disease","Nexviazyme (Enzyme Replacement Therapy) ","\nPhase 3\n","NCT02782741","Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease","Active, not recruiting",100,"Primary Completion: March 19, 2020\nStudy Completion: May 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Rare disease","Nexviazyme (Enzyme Replacement Therapy) ","\n• Phase 2\n• Phase 3\n","NCT02032524","Avalglucosidase Alfa Extension Study","Active, not recruiting",19,"Primary Completion: March 18, 2022\nStudy Completion: March 18, 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare disease","olipudase alfa ","\nPhase 2\n","NCT02004704","A Long-Term Study of Olipudase Alfa\nin Patients With Acid Sphingomyelinase Deficiency","Active, not recruiting",25,"Primary Completion: February 29, 2024\nStudy Completion: February 29, 2024","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare disease","olipudase alfa ","\n• Phase 2\n• Phase 3\n","NCT02004691","Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency","Active, not recruiting",36,"Primary Completion: October 17, 2019\nStudy Completion: October 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","Recruiting",224,"Primary Completion: October 2023\nStudy Completion: June 2025","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04269551","A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease","Active, not recruiting",12,"Primary Completion: January 5, 2022\nStudy Completion: January 5, 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 3\n","NCT04161495","A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand\nFactor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","Active, not recruiting",159,"Primary Completion: January 2022\nStudy Completion: January 2022","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","Recruiting",25,"Primary Completion: August 9, 2023\nStudy Completion: December 2026","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","Recruiting",244,"Primary Completion: October 2026\nStudy Completion: October 2026","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","SAR445136 (Ex Vivo ZFN Gene-Edited Cell Therapy)","\n• Phase 1\n• Phase 2\n","NCT03653247","A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease","Recruiting",8,"Primary Completion: November 2023\nStudy Completion: November 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03549871","A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","Active, not recruiting",80,"Primary Completion: September 2022\nStudy Completion: September 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","sutimlimab (anti-complement C1s mAb)","\nPhase 3\n","NCT03347422","A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion","Active, not recruiting",40,"Primary Completion: December 2021\nStudy Completion: December 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 1\n• Phase 2\n","NCT02554773","An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B","Active, not recruiting",37,"Primary Completion: August 2023\nStudy Completion: August 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With BIVV020","Recruiting",18,"Primary Completion: May 2023\nStudy Completion: May 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 1\n","NCT04770935","To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)","Recruiting",9,"Primary Completion: November 4, 2021\nStudy Completion: November 22, 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Other"]
["Rare blood disorders","efanesoctocog alfa (rFVIIIFc - vWF - XTEN)","\nPhase 3\n","NCT04759131","Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","Recruiting",65,"Primary Completion: February 2023\nStudy Completion: February 2023","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT04669600","A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)","Active, not recruiting",12,"Primary Completion: February 14, 2022\nStudy Completion: January 30, 2024","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04661033","Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)","Recruiting",23,"Primary Completion: December 2023\nStudy Completion: December 2023","• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)","Recruiting",85,"Primary Completion: October 2022\nStudy Completion: September 2023","• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment"]
["Vaccine","Meninge Vaccine\nAfrica, Middle East","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa","Recruiting",1332,"Primary Completion: August 16, 2022\nStudy Completion: August 16, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, North America","\nPhase 3\n","NCT04084769","Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone\nor Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","Completed",570,"Primary Completion: September 14, 2020\nStudy Completion: September 14, 2020","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","New Pertussis Vaccine, North America","\nPhase 1\n","NCT03958799","A Study to Describe the Safety Profile and Compare the Immune Response of 4\nDifferent Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada","Completed",71,"Primary Completion: April 6, 2021\nStudy Completion: April 6, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, Greater Europe","\nPhase 3\n","NCT03890367","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","Completed",707,"Primary Completion: October 14, 2020\nStudy Completion: October 14, 2020","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine\nAfrica, Middle-East","\nPhase 3\n","NCT03869866","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","Recruiting",330,"Primary Completion: December 25, 2021\nStudy Completion: December 25, 2021","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine\nLatin America, North America","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","Recruiting",1070,"Primary Completion: May 2023\nStudy Completion: May 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, Asia Pacific, Greater Europe, Latin America","\nPhase 3\n","NCT03630705","Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","Recruiting",525,"Primary Completion: April 9, 2022\nStudy Completion: April 9, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, Greater Europe","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","Recruiting",1540,"Primary Completion: November 2023\nStudy Completion: November 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, North America","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","Recruiting",2628,"Primary Completion: September 28, 2023\nStudy Completion: September 28, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Dengue Vaccine, Asia Pacific, Latin America ","\n","NCT02948933","Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine","Active, not recruiting",30000,"Primary Completion: October 18, 2024\nStudy Completion: October 18, 2024","• Observational Model: Cohort\n• Time Perspective: Prospective"]
["Vaccine","Next Gen Flu, North America","\nPhase 1\n","NCT04451954","Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","Active, not recruiting",210,"Primary Completion: September 2021\nStudy Completion: September 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Adacel Quadra Vaccine, Africa, Middle East","\nPhase 4\n","NCT04300192","Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","Recruiting",350,"Primary Completion: June 16, 2022\nStudy Completion: June 16, 2022","• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","HSV Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04222985","Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2","Active, not recruiting",381,"Primary Completion: May 2024\nStudy Completion: May 2024","• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Vaccine","Flu QIV SHZ – CN, Asia Pacific","\nPhase 3\n","NCT04210349","Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","Completed",7106,"Primary Completion: December 2, 2020\nStudy Completion: December 2, 2020","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Next Gen Flu, North America","\nPhase 1\n","NCT04144179","Recombinant Influenza Vaccine Containing Different H3 Antigens in Healthy Adults 18 to 30 Years of Age","Completed",150,"Primary Completion: February 24, 2020\nStudy Completion: February 24, 2020","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, North America","\nPhase 3\n","NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","Active, not recruiting",471,"Primary Completion: April 1, 2020\nStudy Completion: April 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","vYF Vaccine, North America","\n• Phase 1\n• Phase 2\n","NCT04142086","Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults","Completed",73,"Primary Completion: June 24, 2021\nStudy Completion: June 24, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Flu QIV HD Vaccine, Greater Europe","\nPhase 3\n","NCT04137887","Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","Suspended",121000,"Primary Completion: August 31, 2024\nStudy Completion: August 31, 2024","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen in Pediatric and Adult Populations and as Single Booster Dose to a Subset of Adults","Completed",1010,"Primary Completion: September 15, 2020\nStudy Completion: August 22, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Rabies Vaccine, Greater Europe","\nPhase 3\n","NCT03965962","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","Completed",640,"Primary Completion: December 22, 2020\nStudy Completion: July 1, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Rabies Vaccine\nAsia Pacific","\nPhase 3\n","NCT04594551","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adults in Thaïland","Completed",201,"Primary Completion: March 2, 2021\nStudy Completion: June 23, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Skypac\nNorth America","\nPhase 2\n","NCT04583618","Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","Recruiting",750,"Primary Completion: August 2021\nStudy Completion: January 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Flu seasonal Vaccine, Asia Pacific","\nPhase 3\n","NCT04537234","Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD)\nCompared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","Completed",165,"Primary Completion: February 9, 2021\nStudy Completion: February 9, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","COVID-19, North America","\n• Phase 1\n• Phase 2\n","NCT04537208","Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","Active, not recruiting",440,"Primary Completion: November 2021\nStudy Completion: November 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Flu QIV HD Vaccine, Asia Pacific","\nPhase 3\n","NCT04498832","Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD)\nCompared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","Completed",2100,"Primary Completion: January 14, 2021\nStudy Completion: January 14, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Vaccine","RSV Infant, Latin America","\n• Phase 1\n• Phase 2\n","NCT04491877","Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","Recruiting",300,"Primary Completion: September 2022\nStudy Completion: June 2023","• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine, Asia Pacific, Greater Europe","\nPhase 3\n","NCT04490018","Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","Recruiting",464,"Primary Completion: February 12, 2022\nStudy Completion: February 12, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Vaccine","Rabies Vaccine, Asia Pacific","\nPhase 3\n","NCT04478084","Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post- Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","Recruiting",376,"Primary Completion: February 2022\nStudy Completion: June 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Shanta Fully Liquid Hexavalent Vaccine, Asia Pacific","\nPhase 3\n","NCT04429295","Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","Active, not recruiting",460,"Primary Completion: February 26, 2021\nStudy Completion: October 27, 2021","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","Skypac, North America","\nPhase 2\n","NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","Recruiting",840,"Primary Completion: July 6, 2023\nStudy Completion: July 6, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","vYF Vaccine, North America","\nPhase 2\n","NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","Recruiting",570,"Primary Completion: December 2, 2021\nStudy Completion: December 1, 2026","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","COVID-19, Greater Europe, Latin America, Asia Pacific, Africa and Middle-East, North America","\nPhase 3\n","NCT04904549","Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older","Recruiting",21046,"Primary Completion: January 27, 2023\nStudy Completion: January 27, 2023","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge B, \nLatin America, Greater Europe, North America","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","Recruiting",1800,"Primary Completion: April 2025\nStudy Completion: April 2025","• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment"]
["Vaccine","COVID-19 mRNA, \nLatin America,North America","\n• Phase 1\n• Phase 2\n","NCT04798027","Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","Recruiting",333,"Primary Completion: November 11, 2022\nStudy Completion: November 11, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","COVID-19,\nLatin America,North America","\n• Phase 2\n• Phase 3\n","NCT04762680","Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older","Recruiting",5414,"Primary Completion: December 24, 2022\nStudy Completion: December 24, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention"]
["Vaccine","Flu seasonal Vaccine North America","\nPhase 2\n","NCT04969276","Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or\nSingly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","Recruiting",300,"Primary Completion: February 2, 2022\nStudy Completion: February 2, 2022","• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]
["Vaccine","Meninge Vaccine Greater Europe","\nPhase 3\n","NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a Booster Dose in Children Vaccinated 5 Years Earlier as Toddlers","Not yet recruiting",250,"Primary Completion: November 8, 2022\nStudy Completion: November 8, 2022","• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention"]